ES2033086T3 - Un procedimiento para la preparacion de una composicion farmaceutica. - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica.

Info

Publication number
ES2033086T3
ES2033086T3 ES198989300856T ES89300856T ES2033086T3 ES 2033086 T3 ES2033086 T3 ES 2033086T3 ES 198989300856 T ES198989300856 T ES 198989300856T ES 89300856 T ES89300856 T ES 89300856T ES 2033086 T3 ES2033086 T3 ES 2033086T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
pharmaceutical composition
aqueous
fluids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198989300856T
Other languages
English (en)
Spanish (es)
Inventor
Kozo Cno Sankyo Company Limited Kurihara
Masaru Cno Sankyo Company Limited Murano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP63183127A external-priority patent/JP2632010B2/ja
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2033086T3 publication Critical patent/ES2033086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES198989300856T 1988-01-29 1989-01-27 Un procedimiento para la preparacion de una composicion farmaceutica. Expired - Lifetime ES2033086T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1912588 1988-01-29
JP11163988 1988-05-10
JP63183127A JP2632010B2 (ja) 1988-01-29 1988-07-22 シクロスポリン製剤

Publications (1)

Publication Number Publication Date
ES2033086T3 true ES2033086T3 (es) 1993-03-01

Family

ID=27282507

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198989300856T Expired - Lifetime ES2033086T3 (es) 1988-01-29 1989-01-27 Un procedimiento para la preparacion de una composicion farmaceutica.

Country Status (8)

Country Link
US (1) US4990337A (enExample)
EP (1) EP0327280B1 (enExample)
AU (1) AU609242B2 (enExample)
CA (1) CA1326995C (enExample)
DE (1) DE68900991D1 (enExample)
ES (1) ES2033086T3 (enExample)
GR (1) GR3004611T3 (enExample)
HK (1) HK35697A (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) * 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
CA2038744C (en) * 1990-03-23 2002-01-08 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition containing slightly water-soluble drug
EP0584238A1 (en) * 1991-05-17 1994-03-02 Chiron Corporation INHIBITOR OF NF-$g(k)B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
EP1142568A1 (en) 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
WO1994008538A1 (fr) * 1992-10-22 1994-04-28 Aktsionernoe Obschestvo 'olvik' Membrane oculaire medicinale et son procede de production
CA2161143A1 (en) † 1993-04-20 1994-10-27 Monika Fleck New pharmaceutical preparations comprising cyclosporin for oral administration
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
ES2308955T5 (es) 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
FR2711982B1 (fr) * 1993-11-02 1996-01-19 Saint Gobain Vitrage Canal de transfert et de conditionnement de verre en fusion.
CA2185803C (en) * 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
SK164796A3 (en) 1994-11-03 1997-06-04 Dresden Arzneimittel Novel cyclosporine preparation forms for oral administration of and process for producing them
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
JP2000516244A (ja) 1996-08-22 2000-12-05 リサーチ・トライアングル・ファーマシューティカルズ 水不溶性物質の微粒子を含む組成物およびその製造方法
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
ATE275963T1 (de) 1997-01-30 2004-10-15 Novartis Pharma Gmbh Ölfreie pharmazeutische zusammensetzung welche cyclosporin enthält
DE19724605A1 (de) * 1997-06-11 1998-12-17 Sueddeutsche Kalkstickstoff Hydrophile, homogene Monogycerid-Formulierungen und Verfahren zu deren Herstellung
IN188719B (enExample) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
ATE497384T1 (de) 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
DE19810655A1 (de) * 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
EP0976394A1 (en) * 1998-07-30 2000-02-02 Biosearch Italia S.p.A. New injectable formulations
HK1042856B (zh) 1998-11-20 2007-07-27 Skyepharma Canada Inc. 可分散的磷脂稳定的微粒
US6638522B1 (en) 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
DE60020382T2 (de) * 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001032143A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7060672B2 (en) * 2001-10-19 2006-06-13 Isotechnika, Inc. Cyclosporin analog formulations
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
MX2007011250A (es) 2005-03-21 2007-11-14 Ivax Pharmaceuticals Sro Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
JP6608917B2 (ja) 2014-09-26 2019-11-20 ザ ケマーズ カンパニー エフシー リミテッド ライアビリティ カンパニー スルホン化フッ素化、非フッ素化、又は部分フッ素化ウレタン
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE149197C (enExample) * 1902-10-24
US2865859A (en) * 1956-11-09 1958-12-23 Irwin I Lubowe Solubilizing of mineral, vegetable, animal oils for cosmetic, pharmaceutical and industrial purposes
US3678149A (en) * 1970-01-26 1972-07-18 Samuel J Prigal Method of enhancing the action of a medicament
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH641356A5 (en) * 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
BE897724A (fr) * 1983-09-09 1984-01-02 Mallien Denis Systeme de communication selective, bidirectionnelle, par radio, entre un poste de commande et plusieurs postes de travail
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
US4612193A (en) * 1983-12-23 1986-09-16 Del Laboratories, Inc. Sty ointment and method of using the same
US4722914A (en) * 1984-05-30 1988-02-02 Motorola Inc. Method of making a high density IC module assembly
DE3580717D1 (de) * 1984-08-02 1991-01-10 Sandoz Ag Pharmazeutische anwendung von (nva)2-cyclosporine.
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin

Also Published As

Publication number Publication date
AU2885389A (en) 1989-08-03
EP0327280A1 (en) 1989-08-09
HK35697A (en) 1997-03-27
DE68900991D1 (de) 1992-04-23
EP0327280B1 (en) 1992-03-18
GR3004611T3 (enExample) 1993-04-28
US4990337A (en) 1991-02-05
CA1326995C (en) 1994-02-15
AU609242B2 (en) 1991-04-26

Similar Documents

Publication Publication Date Title
ES2033086T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
ATE72629T1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
PT850046E (pt) Microemulsoes para utilizacao como veiculos para administracao de compostos activos
ES2157975T3 (es) Soluciones farmaceuticas con solubilidad mejorada.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
MX9203504A (es) Complejo agente: lipido activo de alta proporcion.
ES8602404A1 (es) Metodo de producir complejos solubles en agua de principios activos insolubles en agua y fosfolipidos
AR003933A1 (es) Micelas mixtas, composiciones acuosas que las contienen, procedimiento para la obtencion de las micelas mixtas y empleo de las micelas mixtas.
ES2075468T3 (es) Vehiculos de suministro de farmacos suspendidos en un portador perfluorado no acuoso.
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
DE69211691D1 (de) Pharmazeutische formulierung und pharmazeutisches verfahren
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
AR224111A1 (es) Derivados de 1-oxido de acido penicilanico,desprovistos de actividad terapeutica,utiles como intermediarios en la preparacion de 1,1-dioxido de acido penicilanico farmaceuticamente activos,procedimiento para preparar dichos intermediarios y procedimiento para preparar los 1,1-dioxidos de acido penicilanico farmaceuticamente activos partiendo de dichos intermediarios
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
PE38097A1 (es) NUEVA FORMA CRISTALINA DEL ACIDO 7-([1a, 5a, 6a]-6-AMINO-3-AZABICICLO[3.1.0]HEX-3-IL)-6-FLUOR-1-(2,4-DIFLUOROFENIL)-1,4-DIHIDRO-4-OXO-1,8-NAFTIRIDIN-3-CARBOXILICO ANHIDRO, SAL DEL ACIDO METANOSULFONICO
DK98089A (da) Medikament-lipid-systemer med lav toxicitet
SE8803221D0 (sv) Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
DE3586457D1 (de) Solubilisierungsverfahren im moment der anwendung eines aktiven lipophilen prinzipes in waessriger loesung zum zweck der intravenoesen verabreichung.
ES459244A1 (es) Un procedimiento para la fabricacion de preparados oftalmi- cos de emision lenta
MY110074A (en) Pharmacuetical formulation.
GR3029886T3 (en) Method of preparing a radioactive rhenium complex solution.
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
ES2057528T3 (es) Pdgf-a, pdgf-aa, pdgf-ab, procedimientos de preparacion y medicamentos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 327280

Country of ref document: ES